

Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

GeneGo Inc. is awarded NCI grant for analysis of cancer networks

St. Joseph, Michigan, February 7th, 2005-GeneGo Inc., a leading provider of databases and software for systems biology, announced today that they will be receiving a Phase I SBIR grant from the National Cancer Institute for elucidation and analysis of cellular networks implicated in breast cancer. GeneGo's MetaCore™, an integrated systems biology platform for mining of high-throughput experimental data will be utilized for advanced analysis.

“We are pleased to win this competitive grant from a premier cancer research institution,” said Dr. Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo. “It took our team many years to build tools and pathway content that is comprehensive enough for the analysis of complex human diseases. We will now apply these tools to identify network models and additional patterns in public OMICs cancer data that have been missed by other methods.”

About GeneGo

GeneGo is a Michigan-based company developing systems biology technology for life science research. The Company's original computational platform allows an integration and analysis of different kinds of experimental data (mRNA expression, proteomics, metabolites, phenotypic data etc.) and relevant active chemistry (metabolites, drugs, other xenobiotics) within the framework of biological pathways and networks. GeneGo's first product, MetaCore™, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. GeneGo's second product, MetaDrug™, is designed for medicinal chemists and enables prediction of metabolites and their likely toxicity in humans.

For more information, please visit the company's Web site at www.genego.com .

MetaCore™, MetaBase™ and MetaDrug™ are trademarks of GeneGo, Inc.